First Trust Advisors LP Has $2.85 Million Holdings in Omnicell, Inc. $OMCL

First Trust Advisors LP decreased its position in shares of Omnicell, Inc. (NASDAQ:OMCL) by 35.2% in the 1st quarter, Holdings Channel reports. The firm owned 85,309 shares of the company’s stock after selling 46,411 shares during the quarter. First Trust Advisors LP’s holdings in Omnicell were worth $2,848,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the company. AQR Capital Management LLC raised its stake in Omnicell by 42.1% during the first quarter. AQR Capital Management LLC now owns 17,936 shares of the company’s stock worth $627,000 after buying an additional 5,311 shares during the last quarter. Empowered Funds LLC boosted its position in Omnicell by 14.3% during the first quarter. Empowered Funds LLC now owns 9,953 shares of the company’s stock valued at $348,000 after acquiring an additional 1,243 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Omnicell by 4.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 124,047 shares of the company’s stock valued at $4,337,000 after acquiring an additional 4,866 shares during the last quarter. Jane Street Group LLC grew its holdings in Omnicell by 201.5% during the 1st quarter. Jane Street Group LLC now owns 163,664 shares of the company’s stock worth $5,722,000 after acquiring an additional 109,382 shares during the period. Finally, Creative Planning raised its position in shares of Omnicell by 16.7% in the 2nd quarter. Creative Planning now owns 9,390 shares of the company’s stock worth $276,000 after acquiring an additional 1,347 shares in the last quarter. 97.70% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, EVP Nnamdi Njoku sold 3,090 shares of the company’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $43.22, for a total transaction of $133,549.80. Following the completion of the sale, the executive vice president owned 154,785 shares in the company, valued at approximately $6,689,807.70. This represents a 1.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Corey J. Manley sold 5,025 shares of Omnicell stock in a transaction on Monday, May 18th. The stock was sold at an average price of $43.22, for a total transaction of $217,180.50. Following the transaction, the executive vice president directly owned 112,783 shares in the company, valued at $4,874,481.26. This represents a 4.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 2.92% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on OMCL. Wells Fargo & Company dropped their price objective on Omnicell from $55.00 to $50.00 and set an “overweight” rating on the stock in a research note on Friday, July 31st. KeyCorp dropped their price target on Omnicell from $70.00 to $65.00 and set an “overweight” rating on the stock in a research note on Friday, July 31st. Zacks Research cut Omnicell from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. Wall Street Zen raised shares of Omnicell from a “buy” rating to a “strong-buy” rating in a research report on Sunday, May 10th. Finally, Craig Hallum reiterated a “buy” rating and issued a $55.00 price objective on shares of Omnicell in a research note on Wednesday, April 29th. Seven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, Omnicell presently has an average rating of “Moderate Buy” and an average price target of $57.86.

Omnicell Stock Performance

Shares of OMCL stock opened at $36.16 on Friday. The firm has a market capitalization of $1.64 billion, a PE ratio of 43.05, a price-to-earnings-growth ratio of 1.01 and a beta of 0.98. The firm has a fifty day simple moving average of $41.41 and a two-hundred day simple moving average of $40.63. The company has a current ratio of 1.64, a quick ratio of 1.43 and a debt-to-equity ratio of 0.13. Omnicell, Inc. has a 12 month low of $29.06 and a 12 month high of $55.00.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Thursday, July 30th. The company reported $0.94 earnings per share for the quarter, beating analysts’ consensus estimates of $0.47 by $0.47. The firm had revenue of $312.21 million for the quarter, compared to analyst estimates of $310.21 million. Omnicell had a net margin of 3.13% and a return on equity of 5.66%. The business’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same period last year, the firm earned $0.45 earnings per share. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. Analysts forecast that Omnicell, Inc. will post 1.31 EPS for the current fiscal year.

Omnicell Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.